Humoral immune-response to a SARS-CoV-2-BNT162b2 booster in inflammatory arthritis patients who received an inactivated virus vaccine
- 13 April 2022
- journal article
- letter
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 81 (9), 1338-1340
- https://doi.org/10.1136/annrheumdis-2022-222189
Abstract
No abstract availableFunding Information
- PANLAR (Beca Estímulo a la Investigación PANLAR 2021)
This publication has 5 references indexed in Scilit:
- Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseasesAnnals Of The Rheumatic Diseases, 2022
- Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous dosesThe Lancet Rheumatology, 2021
- China’s COVID vaccines have been crucial — now immunity is waningNature, 2021
- Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case seriesAnnals Of The Rheumatic Diseases, 2021
- A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interactionNature Biotechnology, 2020